Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1637 1639 1675 1682 1684
This examiner grants 76% of resolved cases
Jessica Danielle Parisi is an examiner in Tech Center 1600 and Art Unit 1634, with 99 resolved cases. Her allowance rate of 75.8% indicates a high probability of success for patent applicants. This 75.8% rate suggests that three out of four applications result in a grant. The 99 resolved cases provide a representative sample of the outcomes in this art unit.
The median days to allowance for her cases is 1277. This 1277-day metric provides a benchmark for the time required to reach a successful resolution. For practitioners, the 1277 days to allowance is an important piece of information for managing client expectations and project timelines. This 1277-day figure reflects the typical pace of prosecution within Tech Center 1600 for this examiner.
The interview lift of 32.3% highlights the value of direct communication with the examiner. This 32.3% lift suggests that applications are significantly more likely to be allowed if an interview is conducted. When combined with the 75.8% base allowance rate, the 32.3% lift underscores the effectiveness of oral advocacy. Practitioners should consider the 32.3% lift as a primary strategy for managing the 99 resolved cases in Art Unit 1634.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17922049 | DNA END REPAIR REAGENT AND KIT THEREOF, DNA LIBRARY CONSTRUCTION KIT, AND METHOD FOR CONSTRUCTING DNA LIBRARY | Final Rejection | BOE TECHNOLOGY GROUP CO., LTD. |
| 18636580 | SYSTEM AND METHOD FOR AUTOMATED REPEAT SEQUENCING | Non-Final OA | Life Technologies Corporation |
| 18525142 | METHODS AND SYSTEMS FOR ENGINEERING ANTIBODIES, AND ANTIGEN-BINDING FRAGMENTS THEREOF, TO HAVE ALTERED CHARACTERISTICS | Non-Final OA | 10x Genomics, Inc. |
| 18511791 | METHODS FOR ANALYZING NUCLEIC ACIDS | Non-Final OA | 10X Genomics, Inc. |
| 17773333 | A METHOD TO PREPARE PERSONALIZED TARGET-IRRELEVANT GUIDE RNA POOL FOR CRISPR | Final Rejection | Siemens Healthcare Diagnostics, Inc. |
| 17393994 | IN-SITU SPATIAL TRANSCRIPTOMICS AND PROTEOMICS | Non-Final OA | Massachusetts Institute of Technology |
| 18248215 | MULTIPLEXED METHYLATED DNA IMMUNOPRECIPITATION SEQUENCING TO STUDY DNA METHYLATION USING LOW AMOUNTS OF DNA | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17098912 | MAGNETIC CAPTURE BEAD MEDIATED MOLECULAR BARCODING OF NUCLEIC ACID TARGETS IN SINGLE PARTICLES AND COMPOSITIONS FOR USE IN THE SAME | Non-Final OA | Becton, Dickinson and Company |
| 18414337 | METHODS FOR DETECTING PEPTIDE/MHC/TCR BINDING | Non-Final OA | Prognosys Biosciences, Inc. |
| 17620605 | METHODS FOR DUPLEX SEQUENCING OF CELL-FREE DNA AND APPLICATIONS THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 17029756 | CELL POPULATION ANALYSIS USING SINGLE NUCLEOTIDE POLYMORPHISMS FROM SINGLE CELL TRANSCRIPTOMES | Final Rejection | Fred Hutchinson Cancer Research Center |
| 18576216 | METHOD FOR ANALYZING THE ABILITY OF TARGET NUCLEIC ACID SEQUENCES TO IMPACT GENE EXPRESSION | Non-Final OA | Fred Hutchinson Cancer Center |
| 18567989 | ORTHOGONAL HYBRIDIZATION | Non-Final OA | Illumina, Inc. |
| 17090454 | Evaluating Genomic Variation Using Repetitive Nucleic Acid Sequences | Non-Final OA | Florida State University Research Foundation, Inc. |
| 18315316 | FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOF | Non-Final OA | Genzyme Corporation |
| 18139689 | METHODS AND COMPOSITIONS FOR CLUSTER GENERATION BY BRIDGE AMPLIFICATION | Non-Final OA | ILLUMINA CAMBRIDGE LIMITED |
| 18169970 | Sequence-Specific Targeted Transposition and Selection and Sorting of Nucleic Acids | Final Rejection | Illumina Cambridge Limited |
| 18249511 | METHOD FOR NUCLEIC ACID DETECTION BY OLIGO HYBRIDIZATION AND PCR-BASED AMPLIFICATION | Final Rejection | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT |
| 17848944 | METHODS FOR RECONSTRUCTING SINGLE CELL GENOME | Non-Final OA | Digenomix Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy